BioNTech (BNTX) Stock Price, News & Analysis

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares.
View BNTX analyst ratings or view top-rated stocks.

10 brokers have issued 12 month price targets for BioNTech's stock. Their BNTX share price targets range from $90.00 to $171.00. On average, they predict the company's stock price to reach $120.40 in the next year. This suggests a possible upside of 39.7% from the stock's current price.
View analysts price targets for BNTX or view top-rated stocks among Wall Street analysts.

BioNTech's stock was trading at $105.54 on January 1st, 2024. Since then, BNTX stock has decreased by 18.4% and is now trading at $86.17.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our BNTX earnings forecast.

BioNTech SE (NASDAQ:BNTX) posted its earnings results on Wednesday, March, 20th. The company reported $2.05 EPS for the quarter, missing the consensus estimate of $2.64 by $0.59. The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $2.04 billion. BioNTech had a net margin of 24.26% and a trailing twelve-month return on equity of 4.60%.

ETFs with the largest weight of BioNTech (NASDAQ:BNTX) stock in their portfolio include Morningstar US Small Growth (MSGR), Amplify Treatments, Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX) and iShares Biotechnology ETF (IBB).

33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD).

BioNTech (BNTX) raised $251 million in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

BioNTech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include IMC Chicago LLC (0.00%), Green Alpha Advisors LLC (0.00%), Wealthcare Advisory Partners LLC (0.00%), Park Avenue Securities LLC (0.00%), American National Bank (0.00%) and GAMMA Investing LLC (0.00%).

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.